Case Reports
doi: 10.1093/oxfordjournals.annonc.a058401.
Lack of bone marrow toxicity of high-dose cyclophosphamide associated with inefficient drug metabolism
- PMID: 8117611
- DOI: 10.1093/oxfordjournals.annonc.a058401
Item in Clipboard
Case Reports
Lack of bone marrow toxicity of high-dose cyclophosphamide associated with inefficient drug metabolism
Ann Oncol.
1993 Dec.
Free article
No abstract available
Similar articles
-
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.J Natl Cancer Inst. 1996 Oct 2;88(19):1393-8. doi: 10.1093/jnci/88.19.1393. J Natl Cancer Inst. 1996. PMID: 8827017 Clinical Trial.
-
Cyclophosphamide in solid tumors.Cancer Treat Rev. 1975 Dec;2(4):295-322. doi: 10.1016/s0305-7372(75)80010-7. Cancer Treat Rev. 1975. PMID: 766966 Review. No abstract available.
-
Cyclophosphamide toxicity in Ugandan and American patients with malignant lymphoma.Cancer. 1970 Aug;26(2):462-7. doi: 10.1002/1097-0142(197008)26:2<462::aid-cncr2820260230>3.0.co;2-n. Cancer. 1970. PMID: 5451221 No abstract available.
-
Effect of cleistanthin, a new glycoside, on experimentally induced leukopenia in rats and mice.Arzneimittelforschung. 1971 Jun;21(6):828-30. Arzneimittelforschung. 1971. PMID: 5109270 No abstract available.
-
Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.Semin Oncol. 1996 Feb;23(1 Suppl 1):37-43. Semin Oncol. 1996. PMID: 8629035 Review.
Cited by
-
Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003. Clin Pharmacokinet. 2005. PMID: 16231966 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
